We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New Rapid Lateral Flow Antigen COVID-19 Testing Platform Processes 200-300 People Each Hour and Reports Results in 15 Minutes

By LabMedica International staff writers
Posted on 20 Oct 2020
Print article
Illustration
Illustration
A new rapid lateral flow antigen COVID-19 testing platform gives testers the ability to process an unprecedented 200-300 people each hour and report results within 15 minutes utilizing testing kits from Quidel, BD and Abbott.

The COVID CleanPass system from Apollo Medco (Atlanta, GA, USA) is a mobile app-linked, HIPAA compliant, cloud secure and data-backed COVID-19 testing platform. Straight forward and effortless to operate, its built-in software walks anyone through all and every step of testing. Its trouble-free transportability and total weight of less than 20 pounds makes any location perfect for use. Its bulletproof and waterproof case floats and protects all electronics inside, no matter how harsh the environment. In case of power failure, its eight-hour battery or solar powered panels ensure that testing continues.

Hassle-free, simple to operate, and compatible with worldwide power sources, the COVID CleanPass is a reliable system that is enabling businesses across the globe to reopen and start growing with absolute peace of mind. With its compact form and overhead airline compliance, immediate global deployment to the next viral outbreak is actually possible. Currently, Apollo Medco is beta testing its COVID-19 testing platform and applying for Emergency Use Authorization from the US Food and Drug Administration which is expected in November 2020. Distribution of the new COVID CleanPass system is then expected to begin in late November 2020.

"Our new COVID CleanPass platform is the most advanced, quality-assured, rapid testing platform in the world," said Apollo Medco President & CEO Ken Dunwody. "We've supercharged the overall COVID testing process by delivering fast and accurate results to the patient in an efficient manner. The front-end of our platform includes our Apollo 'Mission Control' diagnostic unit while the back-end of our platform includes our mobile app-linked, cloud secure, HIPAA compliant test reporting system which includes a dynamic Web portal that maps, tracks and reports COVID hot zones in real time."

"Each Apollo Medco testing system is contained in a portable rugged case and includes a battery that lasts 10 hours, iPad with the proprietary mobile app system, time tracking system, printer and a universal lateral flow analysis device. All testing companies will have access to our HIPPA compliant Web portal for accepting new testing requests, scheduling, assigning systems to testers and managing testing assignments. Automatic reporting of all COVID-19 tests through the Apollo Medco COVID CleanPass system will enable testing companies to provide quick, accurate information," added Dunwody.

Related Links:
Apollo Medco

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.